

HEMODYNAMIC DISORDERS, THROMBOEMBOLISM, AND SHOCK 2






 NORMAL HEMOSTASIS COMPRISES A SERIES OF REGULATED PROCESSES THAT CULMINATE IN THE FORMATION OF A <u>BLOOD CLOT</u> THAT LIMITS BLEEDING FROM AN <u>INJURED VESSEL</u>.

 THE PATHOLOGIC COUNTERPART OF HEMOSTASIS IS THROMBOSIS, THE FORMATION OF BLOOD CLOT (THROMBUS) WITHIN NON-TRAUMATIZED, INTACT VESSELS.




 HEMOSTASIS IS PROCESS INVOLVING <u>PLATELETS</u>, <u>CLOTTING FACTORS</u>, AND <u>ENDOTHELIUM</u> THAT OCCURS AT THE SITE OF VASCULAR INJURY AND CULMINATES IN THE FORMATION OF A BLOOD CLOT, WHICH SERVES TO PREVENT OR LIMIT THE EXTENT OF BLEEDING.

Major Components of Hemostasis




)




THE GENERAL SEQUENCE OF EVENTS LEADING TO HEMOSTASIS AT A SITE OF VASCULAR INJURY INCLUDE: I . PRIMARY HEMOSTASIS

- <u>1. ARTERIOLAR VASOCONSTRICTION</u>:
- occurs immediately and markedly reduces blood flow to the injured area.
- it is mediated by reflex neurogenic mechanisms.
- it is augmented by endothelin, a potent endothelium-derived vasoconstrictor.
- this effect is transient, however, bleeding would resume if not followed by activation of platelets and coagulation factors.
 A. VASOCONSTRICTION





THE FORMATION OF THE PLATELET PLUG.




- platelets play a critical role in hemostasis by forming the primary plug that initially seals vascular defects and by providing a surface that binds and concentrates activated coagulation factors.
- platelets are disc-shaped anucleate cell fragments that are shed from megakaryocytes in the bone marrow into the bloodstream.

- <u>Their function depends on several factors including:</u>
- Glycoprotein receptors.


LATELETS

- A contractile cytoskeleton
- Awo types of cytoplasmic granules.
- <u>α-granules</u> have the adhesion molecule p-selectin, and contain proteins involved in coagulation.
- dense (or δ) granules contain ADP and ATP, ionized calcium, serotonin, and epinephrine.



PLATELETS UNDERGO A SEQUENCE OF REACTIONS AFTER A TRAUMATIC VASCULAR INJURY THAT CULMINATE IN THE FORMATION OF A PLATELET PLUG

- <u>1. PLATELET ADHESION:</u>
- is mediated via interactions with vwf, which acts as a bridge between the platelet surface receptor glycoprotein ib (gpib) and exposed collagen.






- <u>A. CHANGES IN SHAPE</u> from smooth discs to spiky "sea urchins" with greatly increased surface area.
 - alterations in glycoprotein iib/iiia that increase its affinity for fibrinogen
 - the translocation of negatively charged phospholipids to the platelet surface

- **B. SECRETION OF GRANULE CONTENTS, e.g.**
- ✓ THROMBIN: ACTIVATES PLATELETS
- ✓ ADP: CREATE AN ADDITIONAL ROUNDS OF PLATELET ACTIVATION.
- ✓ THROMBOXANEA2 (TXA2): A POTENT INDUCER OF PLATELET AGGREGATION.

3. PLATELET AGGREGATION FOLLOWS THEIR ACTIVATION.


 The conformational change in glycoprotein iib/iiia allows binding of fibrinogen that forms bridges between adjacent platelets, leading to their aggregation.

- ✓ fibrinogen cause reversible aggregation
- ✓ thrombin cause irreversible aggregation (converts fibrinogen into insoluble fibrin).
- \checkmark cytoskeleton cause contraction of the plug.





- DEPOSITION OF FIBRIN.
 - VASCULAR INJURY EXPOSES TISSUE FACTOR AT THE SITE OF INJURY.
 - TISSUE FACTOR BINDS AND ACTIVATES FACTOR <u>VII</u>, SETTING IN MOTION A CASCADE OF REACTIONS THAT CULIMINATES IN THROMBIN GENERATION.




• MI. CLOT STABILIZATION AND RESORPTION:

 POLYMERIZED FIBRIN AND PLATELET AGGREGATES UNDERGO CONTRACTION TO FORM A SOLID, PERMANENT PLUG THAT PREVENTS FURTHER HEMORRHAGE.

 ENTRAPPED RED CELLS AND LEUKOCYTES ARE ALSO FOUND IN HEMOSTATIC PLUGS, IN PART DUE TO ADHERENCE OF LEUKOCYTES TO P-SELECTIN EXPRESSED ON ACTIVATED PLATELET

 AT THIS STAGE, COUNTERREGULATORY MECHANISMS (E.G., TISSUE PLASMINOGEN ACTIVATOR, T-PA MADE BY ENDOTHELIAL CELLS) ARE SET INTO MOTION THAT LIMIT CLOTTING TO THE SITE OF INJURY, AND EVENTUALLY LEAD TO CLOT RESORPTION AND TISSUE REPAIR.






 the coagulation cascade is a series of amplifying enzymatic reactions that lead to the deposition of <u>an insoluble</u> fibrin clot.

each reaction step involves an <u>enzyme</u> (an activated coagulation factor), a <u>substrate</u> (an inactive proenzyme form of a coagulation factor), and a <u>cofactor</u> (a reaction accelerator).

 these components are assembled on a negatively charged phospholipid surface, which is provided by activated platelets. assembly of reaction complexes also depends on calcium





vitamin K antagonists

Mnemonic for Vitamin K Dependent Clotting Factors

"Two plus seven is nine NOT ten!"

27910


Coagulation cascade has traditionally been divided into the extrinsic and intrinsic pathways



- <u>1.THE PROTHROMBIN TIME (PT)</u>
- ASSAY ASSESSES THE FUNCTION OF THE PROTEINS IN THE <u>EXTRINSIC PATHWAY (FACTORS VII,</u> X, V, II (PROTHROMBIN), AND FIBRINOGEN).
- THE PARTIAL THROMBOPLASTIN TIME (PTT)
- ASSAY SCREENS THE FUNCTION OF THE PROTEINS IN THE <u>INTRINSIC PATHWAY</u> (FACTORS XII, XI, IX, VIII, X, V, II, AND FIBRINOGEN.

AMONG THROMBIN'S MOST IMPORTANT ACTIVITIES ARE THE FOLLOWING:

- 1. CONVERSION OF FIBRINOGEN INTO CROSSLINKED FIBRIN.
- THROMBIN DIRECTLY CONVERTS SOLUBLE FIBRINOGEN INTO FIBRIN MONOMERS THAT
 POLYMERIZE INTO AN INSOLUBLE FIBRIL.
- <u>2.PLATELET ACTIVATION.</u>
- <u>4. ANTI-COAGULANT EFFECTS.</u>
- ENCOUNTERING NORMAL ENDOTHELIUM, THROMBIN CHANGES FROM A PROCOAGULANT TO AN ANTICOAGULANT.



FACTORS THAT LIMIT COAGULATION.

- COAGULATION MUST BE RESTRICTED TO THE SITE OF VASCULAR INJURY TO PREVENT DANGEROUS CONSEQUENCES THROUGH:
- <u>1.SIMPLE DILUTION:</u>
- BLOOD FLOWING AT THE SITE OF INJURY WASHES OUT ACTIVATED COAGULATION FACTORS, WHICH ARE RAPIDLY REMOVED BY THE LIVER.
- 2.REQUIREMENT FOR NEGATIVELY CHARGED PHOSPHOLIPIDS
- <u>3. FIBRINOLYTIC CASCADE</u>
- THROUGH THE ENZYMATIC ACTIVITY OF PLASMIN, WHICH BREAKS DOWN FIBRIN AND INTERFERES WITH ITS POLYMERIZATION.

fibrinolytic cascade

Plasminogen activators

Tissue plasminogen activator (tPA), urokinase, streptokinase staphylokinase, vampire bat PA

PAI -1 (inhibits tPA, present in blood in small concentration)

Cleave plasminogen into active plasmin

Plasminogen Plasmin

Fibrin

Degrades fibrin clot, core of thrombus


α_2 -antiplasmin

(physiological inhibitor of plasmin present in blood in concentration 6-8X exceeding therapeutic dose of plasmin)

Fibrin degradation products



 AN ELEVATED LEVEL OF BREAKDOWN PRODUCTS OF FIBRINOGEN (D-DIMERS) ARE A USEFUL CLINICAL MARKERS OF SEVERAL THROMBOTIC STATES







 THE BALANCE BETWEEN THE ANTICOAGULANT AND PROCOAGULANT ACTIVITIES OF ENDOTHELIUM OFTEN DETERMINES WHETHER CLOT FORMATION, PROPAGATION, OR DISSOLUTION OCCURS.

.PLATELET INHIBITORY EFFECTS:

SERVE AS A BARRIER THAT SHIELDS PLATELETS FROM SUBENDOTHELIAL VWF AND COLLAGEN.

- ✓ RELEASES A NUMBER OF FACTORS THAT INHIBIT PLATELET ACTIVATION AND AGGREGATION. AMONG THE MOST IMPORTANT ARE PROSTACYCLIN (PGI2), NITRIC OXIDE (NO).
- ✓ ENDOTHELIAL CELLS BIND AND ALTER THE ACTIVITY OF THROMBIN, WHICH IS ONE OF THE MOST POTENT ACTIVATORS OF PLATELETS.
- 2. ANTICOAGULANT EFFECTS.
- NORMAL ENDOTHELIUM SHIELDS COAGULATION FACTORS FROM TISSUE FACTOR IN VESSEL WALLS
 AND EXPRESSES MULTIPLE FACTORS THAT ACTIVELY OPPOSE COAGULATION:
- MOST NOTABLY <u>THROMBOMODULIN, ENDOTHELIAL PROTEIN C RECEPTOR, HEPARIN-LIKE MOLECULES,</u> <u>AND TISSUE FACTOR PATHWAY INHIBITOR.</u>

